Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan PLC are very excited about this new contract with a top 3 pharma company, this is a £4m RSV (respiratory syncytial virus) human challenge study clinical trial which
This RNS validates the refocus of Venn Life Sciences since Open Orphan took over the company last June to secure long-term partnership contracts which deliver recurring revenues for the business.
This RNS is the very exciting start to a substantial amount of COVID-19 work that we will be doing for the remainder of this year and throughout next year.
Cathal Friel, Executive Chairman of Open Orphan, said:
This is a quite exciting new area of business for Open Orphan’s subsidiary hVIVO in London. Not only does hVIVO have the world’s only 24-bed quarantine clinic for testing vaccines
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is
Positive results from thePhase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet.